Skip to main content
Phase II Coming Soon Neurology

Monthly Injectable for Chronic Migraine Prevention

Evaluating a monthly injectable CGRP antagonist for the preventive treatment of chronic migraine in adults who have failed at least two prior preventive therapies.

Duration
48 weeks
Visits
10 visits
Compensation
Up to $1,500

Study Overview

This Phase II study evaluates a novel CGRP receptor antagonist administered as a monthly subcutaneous injection in adults with chronic migraine (≥15 headache days/month). The 24-week double-blind period is followed by a 24-week open-label extension. Primary endpoint is mean change from baseline in monthly migraine days at Week 24.

Eligibility Criteria

You May Qualify If:

  • Adults aged 18–65
  • Chronic migraine (≥15 headache days/month for ≥3 months)
  • Failed ≥2 prior preventive migraine therapies
  • Able to distinguish migraine from other headache types

You May Not Qualify If:

  • More than 15 days/month of acute headache medication use
  • Hemiplegic or basilar migraine
  • History of stroke or TIA within 12 months
  • Serious psychiatric condition requiring inpatient treatment

Study Locations

Tampa Main OfficeSt. Petersburg Office

Apply for This Study

Complete this brief form and our team will contact you within 1 business day.

Questions? Call us directly:

(813) 815-7327
Back to All Studies